MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE AND COMPARE

非类固醇抗炎药(NSAIDs)是应用最广泛的药物之一 处方药类别。虽然总体上是安全的，但这类 用药可能与严重的胃肠道和肾脏有关 不良反应，既有疗效又有毒性，归因于 环氧合酶抑制(COX)。环氧合酶最近被 发现存在两种与维持有关的亚型COX-1 前列腺素和环氧合酶-2，参与产生 炎性前列腺素。目前可用的非类固醇抗肿瘤药物 炎症药物(NSAIDs)的特征是双重的COX-1和 COX-2抑制剂[1，2]。这是一种双盲、安慰剂对照的， 多中心、双模拟、平行分组研究，以评估和比较 多剂量选择性COX-2抑制剂MK-0966的作用 消炎痛和安慰剂对65-80岁受试者肾功能的影响 肌酐清除量为30-80毫升/分钟的年龄。

Nonsteroidal anti-inflammatory drugs (NSAIDs) are on of the most widely prescribed class of medications. While generally safe, this class of medications may be associated with serious gastrointestinal and renal adverse effects, both there efficacy and toxicity is attributed to the inhibition of cyclo-oxygenase (COX). Cyclo-oxygenase has recently been discovered to exist in two isoforms COX-1 which is involved in maintenance prostaglandins and COX-2 which is involved in the production of inflammatory prostaglandins. Currently available nonsteroidal anti- inflammatory drugs (NSAIDs) have been characterized as dual COX-1 and COX-2 inhibitors [1,2]. This is a double-blind, placebo-controlled, multicenter, double-dummy, parallel group study to evaluate and compare the effects of multiple doses of the selective COX-2 inhibitor MK-0966, indomethacin, and placebo on renal function in subjects 65 to 80 year of age with creatinine clearance 30 to 80 ml/minute.